Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
JCS 2017 Guideline on Management of Vasculitis Syndrome　- Digest Version.
Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Komagata Y, Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigai M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, Wada T, Inoue Y, Uchida HA, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada KE, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugiyama H, Takeno M, Tamura N, Tsutsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Takihara K, Murohara T, Momomura SI; JCS Joint Working Group. Isobe M, et al. Among authors: dobashi h. Circ J. 2020 Jan 24;84(2):299-359. doi: 10.1253/circj.CJ-19-0773. Epub 2020 Jan 18. Circ J. 2020. PMID: 31956163 Free article. Review. No abstract available.
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: dobashi h. Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13. Ann Rheum Dis. 2012. PMID: 22504558 Free article.
Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.
Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S, Yamada H, Wada T, Hirahashi J, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. Sada KE, et al. Among authors: dobashi h. Arthritis Res Ther. 2014 Apr 23;16(2):R101. doi: 10.1186/ar4550. Arthritis Res Ther. 2014. PMID: 24758294 Free PMC article.
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group. Sakai R, et al. Among authors: dobashi h. Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23. Rheumatol Int. 2014. PMID: 24852650
Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators. Ogata A, et al. Among authors: dobashi h. J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834203 Clinical Trial.
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: dobashi h. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi: 10.1186/s13075-015-0583-8. Arthritis Res Ther. 2015. PMID: 25880658 Free PMC article. Clinical Trial.
Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.
Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Takasaki Y, Banno S, Sugihara T, Kobayashi M, Usui J, Yamagata K, Homma S, Dobashi H, Tsuboi N, Ishizu A, Sugiyama H, Okada Y, Arimura Y, Matsuo S, Makino H; for Research Committee of Intractable Vasculitis Syndrome and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan. Sada KE, et al. Among authors: dobashi h. Mod Rheumatol. 2016 Sep;26(5):730-7. doi: 10.3109/14397595.2016.1140274. Epub 2016 Mar 11. Mod Rheumatol. 2016. PMID: 26873424 Free article.
Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
Tahara N, Dobashi H, Fukuda K, Funauchi M, Hatano M, Ikeda S, Joho S, Kihara Y, Kimura T, Kondo T, Matsushita M, Minamino T, Nakanishi N, Ozaki Y, Saji T, Sakai S, Tanabe N, Watanabe H, Yamada H, Yoshioka K, Sasayama S. Tahara N, et al. Among authors: dobashi h. Circ J. 2016 May 25;80(6):1478-83. doi: 10.1253/circj.CJ-15-1305. Epub 2016 May 13. Circ J. 2016. PMID: 27180890 Free article.
215 results